Anthony P Schwarer

Loading... 2 0 20 0 false
Credit Name
Anthony P Schwarer
Full Name
Schwarer, Anthony P
 
 
Loading... 3 0 20 0 false

Publications

Results 1-14 of 14 (Search time: 0.008 seconds).

Publication YearTitleAuthor(s)
17-Dec-2023Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized, placebo-controlled study by the ALLG.Loo, Sun; Roberts, Andrew W; Anstee, Natasha S; Kennedy, Glen A; He, Simon Zhao-Xiong; Schwarer, Anthony P ; Enjeti, Anoop Kumar; D'Rozario, James; Marlton, Paula; Bilmon, Ian; Taper, John M; Cull, Gavin; Tiley, Campbell; Verner, Emma; Hahn, Uwe; Hiwase, Devendra K; Iland, Harry J; Murphy, Nicholas Edward; Ramanathan, Sundra; Reynolds, John; Ong, Doen Ming; Tiong, Ing Soo; Wall, Meaghan; Murray, Michael; Rawling, Tristan; Leadbetter, Joanna; Rowley, Leesa; Latimer, Maya; Yuen, Sam L S; Ting, Stephen B; Fong, Chun Yew ; Morris, Kirk Lachlan; Bajel, Ashish; Seymour, John F; Levis, Mark J; Wei, Andrew H
21-Sep-2023Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.Shanmuganathan, Naranie; Wadham, Carol; Shahrin, NurHezrin; Feng, Jinghua; Thomson, Daniel; Wang, Paul; Saunders, Verity; Kok, Chung Hoow; King, Rob M; Kenyon, Rosalie R; Lin, Ming; Pagani, Ilaria S; Ross, David M; Yong, Agnes S M; Grigg, Andrew P ; Mills, Anthony K; Schwarer, Anthony P ; Braley, Jodi; Altamura, Haley; Yeung, David T; Scott, Hamish S; Schreiber, Andreas W; Hughes, Timothy P; Branford, Susan
3Jan-2023Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Watts, Justin M; Baer, Maria R; Yang, Jay; Prebet, Thomas; Lee, Sangmin; Schiller, Gary J; Dinner, Shira N; Pigneux, Arnaud; Montesinos, Pau; Wang, Eunice S; Seiter, Karen P; Wei, Andrew H; De Botton, Stephane; Arnan, Montserrat; Donnellan, Will; Schwarer, Anthony P ; RĂ©cher, Christian; Jonas, Brian A; Ferrell, P Brent; Marzac, Christophe; Kelly, Patrick; Sweeney, Jennifer; Forsyth, Sanjeev; Guichard, Sylvie M; Brevard, Julie; Henrick, Patrick; Mohamed, Hesham; Cortes, Jorge E
426-Apr-2021The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.Rees, Matthew J ; Wu, Simon; Mokoonlall, Mridula; Dix, Caroline H K; Bryant, Christian E; D'Rozario, James; Schwarer, Anthony P ; Grigg, Andrew P ; Tiong, Ing S 
5Mar-2021Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.Tiong, Ing S ; Dillon, Richard; Ivey, Adam; Teh, Tse-Chieh; Nguyen, Phillip; Cummings, Nicholas; Taussig, David C; Latif, Annie-Louise; Potter, Nicola E; Runglall, Manohursingh; Russell, Nigel H; Raj, Kavita; Schwarer, Anthony P ; Fong, Chun Yew ; Grigg, Andrew P ; Wei, Andrew H
62021Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission.Nguyen, Phillip C; Manos, Kate ; Fong, Chun Y; Schwarer, Anthony P ; Tiong, Ing S ; Wei, Andrew H; Kliman, David; Curtis, David J
72021Acute graft-versus-host disease associated cerebellitis as the cause of pyrexia of unknown origin detected with 18F-FDG-PET/CT.Jewell, Kerry E; Kuzich, James A; Lee, Sze Ting ; Trethowan, Rebecca; Macdonell, Richard A L ; Schwarer, Anthony P 
8Jul-2019Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.Hamadi, Abdullah; Grigg, Andrew P ; Dobie, Gasim; Burbury, Kate L; Schwarer, Anthony P ; Kwa, Faith A; Jackson, Denise E
9Dec-2018A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML.Schwarer, Anthony P ; Butler, Jason; Jackson, Kathryn; Beligaswatte, Ashanka; Martin, Louisa; Kennedy, Glen; Daniela, Zantomio; Lewis, Ian; Hiwase, Devendra; Wight, Joel C ; He, Simon ; Grigg, Andrew; Morris, Kirk; Mollee, Peter; Marlton, Paula
102018Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.Ross, David M; Pagani, Ilaria S; Shanmuganathan, Naranie; Kok, Chung H; Seymour, John F; Mills, Anthony K; Filshie, Robin J; Arthur, Christopher K; Dang, Phuong; Saunders, Verity A; Braley, Jodi; Yong, Agnes S; Yeung, David T; White, Deborah L; Grigg, Andrew P ; Schwarer, Anthony P ; Branford, Susan; Hughes, Timothy P
11Jun-2017Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab eraTamjid, Babak ; Mckendrick, Joseph; Schwarer, Anthony P ; Doig, Rowan; James, Philip; Hosking, Patrick; Hawkes, Eliza A 
1223-May-2017The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.Fox, Lucy C; Cummins, Katherine D; Costello, Ben; Yeung, David; Cleary, Rebecca; Forsyth, Cecily; Tatarczuch, Maciek; Burbury, Kate; Motorna, Olga; Shortt, Jake; Fleming, Shaun; McQuillan, Andrew; Schwarer, Anthony P ; Harrup, Rosemary; Holmes, Amy; Ratnasingam, Sumita; Chan, Kah-Lok; Hsu, Wei-Hsun; Ashraf, Asma; Putt, Faye; Grigg, Andrew P
13Apr-2016Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraJalali, Azim; Ha, Francis J; Chong, Geoff; Grigg, Andrew P ; Mckendrick, Joe; Schwarer, Anthony P ; Doig, Rowan; Hamid, Anis; Hawkes, Eliza A 
1417-Dec-2014TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.Yeung, David T; Osborn, Michael P; White, Deborah L; Branford, Susan; Braley, Jodi A; Herschtal, Alan; Kornhauser, Michael; Issa, Samar; Hiwase, Devendra K; Hertzberg, Mark; Schwarer, Anthony P ; Filshie, Robin; Arthur, Christopher K; Kwan, Yiu Lam; Trotman, Judith; Forsyth, Cecily J; Taper, John; Ross, David M; Beresford, Jennifer; Tam, Constantine; Mills, Anthony K; Grigg, Andrew P ; Hughes, Timothy P